Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
webinar

Emerging tools for the analysis of biologics and biosimilars

In this virtual roundtable, experts explore the uses of nuclear magnetic resonance (NMR) in the analysis of biologics and biosimilars and discuss how recent advances are changing the game.

Meet our participants

Scott Bradley, Principal Research Scientist, Eli Lilly and Company

Scott is a Principal Research Scientist at Eli Lilly and Company. He received his Bachelor of Arts in Chemistry from Cedarville University in 1997 and his PhD in physical organic chemistry and NMR spectroscopy from Purdue University in 2002. Scott held a postdoctoral research position at Eli Lilly and Company from 2002-2005, where he created various NMR pulse sequences and explored new applications of NMR for metabolite identification. After a brief stint at Merck and Company, he returned to Eli Lilly and Company’s Small-Molecule Design and Development department in 2007. Scott is now a part of the Bioproducts Research and Development department, where he develops and applies various NMR techniques to characterise and quantitate biotherapeutics.

Joan Malmstrøm, Principal Scientist, Novo Nordisk

Joan is a Principal Scientist at Novo Nordisk A/S holding a Ph.D. degree in chemistry from the University of Copenhagen and over 20 years of experience with structural elucidation of organic molecules using nuclear magnetic resonance spectroscopy and mass spectrometry as analytical tools. The projects she has been involved in at Novo Nordisk A/S ranges from small molecules (API’s, raw materials/excipients, etc) up to peptides/proteins and large molecular weight polymers. During the past years, one of her main activities has been the development of NMR analytical methods suitable for analysing all kind of molecules included in drug development. These analytical methods are applied at various stages of the development pipeline and GMP validated when needed.

Kelly Sackett, Principal Scientist, Pfizer

Kelly is a Principal Scientist at Pfizer. He undertook graduate training in biophysical characterisation at the Weizmann Institute of Science, post-graduate research in biophysics and SS-NMR at Michigan State University. Kelly’s biopharmaceutical industry career at Pfizer involves leveraging solution NMR approaches toward biomolecular characterisation and project progression of a range of biotherapeutic programs including glycoconjugate vaccines, monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), gene therapies and lipid nanoparticle (LNP) mRNA vaccines. His interests include the development of robust and well characterised processes to support the production of biologic based medicines.